



FOR IMMEDIATE RELEASE

AdvanSource Biomaterials Receives Key ISO Certifications for Design & Manufacture of Polymers for the Medical Device Industry

WILMINGTON, MA, December 3, 2008 --AdvanSource Biomaterials Corporation (NYSE **Alternext US: ASB**), a leading developer of advanced polymer materials for a broad range of medical device applications, today announced that after assessment by the International Organization for Standardization (ISO), the Company's Quality Management System has received ISO certification through SGS United Kingdom Ltd. to ISO13485:2003 and 9001:2000 for the design and manufacture of polymers for the medical device industry. ISO certification is the preeminent worldwide standard for manufacturing and quality control systems.

Commenting on today's announcement, AdvanSource President and CEO Michael Adams said, "The certifications we have just received are recognized by all medical device developers and manufacturers as proof of high product quality. By receiving ISO certification, AdvanSource has reached a major milestone with a focus on continuous improvement as well as expanding its ability to be chosen as a technology partner by both existing and potential customers."

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. The Company is conducting a clinical trial for regulatory approval at two sites in Europe for its CardioPass™ synthetic coronary bypass graft. More information about AdvanSource is available at its website: www.advbiomaterials.com

Forward-Looking Statements:

AdvanSource believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review AdvanSource's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2008 and its Quarterly Reports on Form 10-Q for the periods ended June 30, 2008 and September 30, 2008. AdvanSource assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For Further Information Contact:

Eric Walters
Vice President & CFO
AdvanSource Biomaterials
978-657-0075

Sylvia Dresner
Senior Vice President
VMW Corporate & Investor Relations
212-616-6161



info@advbiomaterials.com

info@vmwcom.com